FDG-PET反应与抗PD-1治疗转移性黑色素瘤的结局
该回顾性分析纳入104例接受抗PD-1治疗的转移性黑色素瘤患者,比较1年时FDG-PET与CT评估的缓解与后续无进展生存的关系。PET完全代谢缓解(CMR)者后续PFS显著优于非CMR者,且多数CT部分缓解(PR)者PET为CMR。
要点
- 1年时CT评估CR仅28%,但PET评估CMR达75%。
- CMR者后续PFS显著优于非CMR者(中位未达到 vs 12.8个月)。
- CT为PR但PET为CMR者后续PFS也显著优于非CMR者。
核心结论
- 1年时FDG-PET的CMR可预测抗PD-1治疗转移性黑色素瘤的长期获益。
- 多数CT评估为PR的患者PET为CMR,且CMR者后续多持续缓解。
研究设计与样本
- 回顾性分析澳大利亚黑色素瘤研究所104例接受抗PD-1为基础免疫治疗的转移性黑色素瘤患者。
- 患者均有基线与1年FDG-PET及CT影像,中位随访30.1个月,98%存活。
- 67%接受抗PD-1单药,31%接受抗PD-1联合伊匹木单抗。
主要发现
- 1年时CT评估:CR 28%、PR 66%、SD 6%;PET评估:CMR 75%、PMR 16%、SMD/PMD 9%。
- CT为PR的患者中68%为PET CMR。
- 1年 landmark后RECIST PFS在CT CR与PR/SD间相似,但CMR者优于非CMR者(中位NR vs 12.8个月;HR 0.06,95%CI 0.02-0.23;P<0.01)。
- CT为PR者中,PR+CMR较PR+非CMR的PFS更优(中位NR vs 12.8个月;HR 0.07,95%CI 0.02-0.27;P<0.01)。
- 78例CMR患者中78%已停止治疗,96%持续缓解。
关键数值与推荐
- CT采用RECIST评估,PET采用EORTC标准评估,缓解编码为CR/CMR、PR/PMR、SD/SMD、PD/PMD。
- PFS从1年landmark起计算。
临床怎么用
- FDG-PET的1年CMR有助于预测抗PD-1治疗的长期获益。
- PET结果可能辅助指导是否停用免疫治疗。
局限性
- 回顾性分析,样本量104例,来自单中心。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immune checkpoint inhibitor therapy has resulted in impressive and durable clinical activity for many cancers including melanoma; however, there remain few reliable predictors for long-term response. This study investigated whether [18F]2-fluoro-2-deoxy-D-glucose (FDG-PET) imaging may better predict long-term outcomes compared with standard computed tomography (CT) response criteria. PATIENTS AND METHODS: Retrospective analysis of metastatic melanoma patients treated with anti-PD-1-based immunotherapy with baseline and 1-year FDG-PET and CT imaging at Melanoma Institute Australia. One-year response was determined using RECIST for CT and EORTC criteria for PET, coded as complete response (CR or CMR), partial response (PR or PMR), stable disease (SD or SMD) or progressive disease (PD or PMD). Progression-free survival (PFS) was determined from the 1-year landmark. RESULTS: Patients (n = 104) were evaluated with median follow-up 30.1 months and 98% remain alive. Most received anti-PD-1 as monotherapy (67%) or combined with ipilimumab (31%). At 1 year, 28% had CR, 66% had PR and 6% had SD on CT, while 75% had CMR, 16% PMR and 9% SMD/PMD on PET. CMR was observed in 68% of patients with PR on CT. RECIST PFS post 1-year landmark was similar in patients with CR versus PR/SD, but improved in patients with CMR versus non-CMR {median not reached [NR] versus 12.8 month; hazard ratio [HR] 0.06 [95% confidence interval (CI) 0.02-0.23]; P < 0.01}. In patients with PR on CT, PFS was improved in patients with PR + CMR versus PR + non-CMR (median NR versus 12.8 months; HR 0.07 [95% CI 0.02-0.27]; P < 0.01). In the 78 CMR patients, 78% had discontinued treatment and 96% had ongoing response. CONCLUSIONS: Whilst only a small proportion of patients have a CR at 1 year, most patients with a PR have CMR on PET. Almost all patients with CMR at 1 year have ongoing response to therapy thereafter. PET may have utility in predicting long-term benefit and help guide discontinuation of therapy.
引用
- Tan AC, Emmett L, Lo S, et al. FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma. Ann Oncol. 2018. PMID: 30137228. doi:10.1093/annonc/mdy330
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。